ClinicalTrials.gg
CompletedNCT00663702Updated Mar 9, 2015Results posted

Phase IIIB Switching From Intravenous to Subcutaneous Study

A Phase 3 interventional study of Abatacept in Arthritis, Rheumatoid, sponsored by Bristol-Myers Squibb. Completed at 30 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-09.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
28th of 63
123 · median 119
Started
2008
with 2 others
Phase 3
26 of 63
2 open now
Registered
20th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 28th largest by enrollment, is one of 3 that started in 2008, is one of 26 in phase 3, and was the 20th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether switching to subcutaneous administration of abatacept will be safe in participants with rheumatoid arthritis who previously received long-term therapy with intravenous abatacept

03

Conditions studied

  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recruitment from 2 Bristol-Myers Squibb (BMS) studies (BMS IM101-029 [NCT00048581] and BMS IM101-102 [NCT00048568]).
  • Completion of final quarterly dosing visit in NCT00048581 or NCT00048568 as follows: US and Canadian participants: Day 1821 visit; Taiwanese participants: Day 1905 visit; Mexican participants: Day 1989 visit.
  • Agreement to participate in BMS IM101-185 (NCT00663702) on final quarterly dosing visit in NCT00048581 or NCT00048568 study as follows: US and Canadian participants: Day 1821 visit; Taiwanese participants: Day 1905 visit; Mexican participants: Day 1989 visit.
  • At the time of completion of the NCT00048581 or NCT00048568 protocol, participant did not meet any criteria requiring their discontinuation.
  • Drug stabilization requirements: Participants who received concomitant medications (disease-modifying antirheumatic drugs, , and nonsteroidal anti-inflammatory drugs) at the time of their last quarterly dosing visit for NCT00048581 or NCT00048568 were required to maintain stable dose levels from the time they signed consent until the end of the first 3 months (Day 85) of the current study.
  • Willingness to self-inject study medication (abatacept) or allow a caregiver to inject study medication.
  • Willingness to adhere to study visit schedule and comply with other protocol requirements.
  • Male or female (not nursing or pregnant)genders, at least 18 years of age. Women of (WOCBP) must have been practicing adequate measures during the study and for up to 10 weeks after the last infusion of study medication in such a manner that the risk of pregnancy was minimized. WOCBP must have had a negative serum or urine pregnancy test result (minimum sensitivity of 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 48 hours prior to the start of study medication.

Exclusion criteria

Exclusion Criteria:

  • The following treatment or therapies should not be started on or after the final quarterly dosing visit from the NCT00048581 or NCT00048568 study: Any biologic; immunoabsorption columns (such as Prosorba columns); mycophenolate mofetil; cyclosporin A or other calcineurin inhibitors; D-penicillamine; any within 3 months of Day 1 or scheduled to receive a live vaccine during the course of the study
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, or a concomitant medical condition that, in the opinion of the Investigator, might have placed the participation at unacceptable risk for study participation
  • Any clinical laboratory test result that was considered to be abnormal or not within acceptable limits on the final quarterly dosing visit of NCT00048581 or NCT00048568. Screening laboratory test results for NCT00663702 were based on the Day 1821 visit of NCT00048581 or NCT00048568 for participants enrolled at sites in the US or Canada and on the Day 1989 visit of NCT00048568 for participants enrolled at sites in Mexico.
  • Imprisonment or involuntarily incarceration for treatment of either a psychiatric or physical (eg, infectious disease) illness
  • Impairment, incapacitation, inability to complete study-related assessments, or illiteracy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    1

    Drug: Abatacept

Interventions

  • Subcutaneous injection, 125 mg/mL, once weekly, 48 months

    Also known as: Orencia, BMS-188667

06

What researchers measure

Primary outcomes

  1. Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Treatment-related Adverse Events (AEs), AEs Leading to Discontinuation, and AEs of Interest (AEIs) at Day 85

    An AE is a new or worsening illness, sign, or symptom or a clinically significant abnormal laboratory test result occurring during the study, regardless of causality, and noted by the investigators. Systemic injection reaction occurring ≤ 24 hours after dosing.

    Time frame: Day 1 (Baseline) through Day 85

  2. Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Treatment-related Adverse Events (AEs), and AEs Leading to Discontinuation

    An AE is a new or worsening illness, sign, or symptom or a clinically significant abnormal laboratory test result occurring during the study, regardless of causality, and noted by the investigators.

    Time frame: Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period

  3. Number of Participants With Hematology Laboratory Values Meeting the Criteria for Marked Abnormality

    LLN=lower limit of normal; ULN=upper limit of normal; preRx=pretreatment. Marked abnormality criteria: Hemoglobin (g/dL) \>3 decrease from preRx. Hematocrit (%)\<0.75\*preRx. Erythrocytes (\*10\^6 c/uL) \<0.75\*preRx. Platelet count (\*10\^9 c/L) \<0.67\*LLN or 1.5\*ULN or, if preRx\<LLN, use \<0.5\*preRx and \<100,000 mm\^3. Leukocytes (\*10\^3 c/uL) \<0.75\*LLN or \>1.25\*ULN or, if preRx\<LLN, use \<0.8\*preRx or \>ULN or, if preRx\>ULN, use \>1.2\*preRx or \<LLN. Eosinophils \>0.750\*10\^3 c/uL. Lymphocytes \<0.750\*10\^3 c/uL or \>7.50\*10\^3 c/uL.

    Time frame: Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period

  4. Number of Participants With Liver and Kidney Function Laboratory Values Meeting the Criteria for Marked Abnormality

    LLN=lower limit of normal; ULN=upper limit of normal; preRx=pretreatment. Marked abnormality criteria: Alkaline phosphatase (U/L) \>2\*ULN or if preRx\>ULN, use 3\*preRx. Alanine aminotransferase (U/L)\>3\*ULN or if preRx\>ULN, use \>4\*preRx. G-glutamyl transferase (U/L)\>2\*ULN or if preRx\>ULN, use \>3\*preRx. Blood urea nitrogen (mg/dL)\>2\*preRx. Creatinine (mg/dL)\>1.5\*preRx.

    Time frame: Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period

  5. Number of Participants With Electrolyte Laboratory Values Meeting the Criteria for Marked Abnormality

    LLN=lower limit of normal; ULN=upper limit of normal; preRx=pretreatment. Sodium: \<0.95\*LLN or \>1.05\*ULN or if preRx\<LLN, \<0.95\*preRx or \>ULN, or if preRx\>ULN,\>1.05\*preRx or \<LLN. Potassium,serum: \<0.9\*LLN or \>1.1\*ULN or if preRx\<LLN, use \<0.9\*preRx or \>ULN or if preRx\>ULN, 1.1\*preRx or \<LLN. Phosphorus: 0.75\*LLN or 1.25\*ULN or, if preRx\<LLN, \<0.67\*preRx or \>ULN or, if preRx\>ULN, \<LLN.

    Time frame: Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period

  6. Number of Participants With Chemistry Laboratory Values Meeting the Criteria for Marked Abnormality

    LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality: .

    Time frame: Day 1 (Baseline) to up to 56 days past the last day of subcutaneous injection in the cumulative study period

  7. Participants With Urinalysis Values Meeting the Criteria for Marked Abnormality

    preRX=pretreatment. For all values analyzed (protein, urine; glucose, urine; blood, urine: leukocyte esterase, urine; white blood cells, urine; red blood cells, urine): If missing preRx, use \>=2 or, if value \>= 4, or if preRx=0 or 0.5, use \>=2 or, if preRx= 1, use \>=3 or, if preRx=2 or 3, use \>=4.

    Time frame: Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period

  8. Number of Participants With Adverse Events of Special Interest

    AEs of special interest are AEs that may be associated with the use of immunomodulatory drugs, such as infections, malignancies, autoimmune disorders, and injection reactions (defined as local injection site reactions and systemic injection reactions occurring within 24 hours of subcutaneous injection).

    Time frame: Day 1 (Baseline) to up to 56 days past the last day of subcutaneous injection in the cumulative study period

  9. Mean Sitting Systolic and Diastolic Blood Pressure (BP)

    BP was measured after the patient had been seated quietly for at least 5 minutes and recorded during the screening visit, during every office visit prior to administration of subcutaneous injections, and at study discharge or 7 days after the last dose for patients who terminated early.

    Time frame: Before injection on Days 1, 29, 57, 85, 169, 253, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, and 1821

  10. Mean Heart Rate

    Heart rate was measured after the patient had been seated quietly for at least 5 minutes and recorded during the screening visit, during every office visit prior to administration of subcutaneous injections, and at study discharge or 7 days after the last dose for patients who terminated early.

    Time frame: Before injection on Days 1, 29, 57, 85, 169, 253, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, and 1821

  11. Mean Temperature

    Temperature was measured after the patient had been seated quietly for at least 5 minutes and recorded during the screening visit, during every office visit prior to administration of subcutaneous injections, and at study discharge or 7 days after the last dose for patients who terminated early.

    Time frame: Before injection on Days 1, 29, 57, 85, 169, 253, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, and 1821

Secondary outcomes

  1. Mean Trough Serum Concentration (Cmin) of Abatacept

    Cmin of abatacept was determined from serum samples.

    Time frame: Days 29, 85, 57, and 85

  2. Percentage of Participants With A Positive Anti-abatacept Response (Based on Enzyme-linked Immunosorbent Assay [ELISA]) at Day 85

    Using the ELISA, any positive (titer of 400 or greater) postbaseline sample was classified as positive immunogenicity. The percentage of participants with at least 1 positive antibody response (anti-abatacept and/or anti-CTLA4-T) during the 85 days was tabulated by antibody specificity and overall.

    Time frame: Day 1 (Baseline) through Day 85

  3. Percentage of Participants With A Positive Anti-abatacept Response (Based on Electrochemiluminescence [ECL] Immunoassay) at Day 85

    Number of participants was tabulated using ECL assay with at least 1 positive abatacept-induced immunogenic response (CTLA4 and possibly Ig, Ig and/or Junction Region) in the first 85 days. Positive response (titers \>10) included: * A missing baseline immunogenicity measurement and a positive immunogenicity response postbaseline * A negative baseline immunogenicity response and a positive immunogenicity response postbaseline * A positive baseline immunogenicity response and a positive immunogenicity response postbaseline that has a titer value strictly greater than the baseline titer value

    Time frame: Day 1 (Baseline) through Day 85

  4. Mean Disease Activity Score 28 Based on C-reactive Protein (DAS 28-CRP) Scores Over Time

    The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), C-reactive protein level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)

    Time frame: Day 1 (Baseline) through Day 1093

  5. Percentage of Participants With Low Disease Activity Score (LDAS) and Disease Activity Score 28 Based on C-reactive Protein (DAS 28-CRP) Remission Over Time:

    LDAS is defined as DAS 28-CRP ≤3.2. DAS 28-CRP remission is defined as DAS 28-CRP \<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), C-reactive protein level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)

    Time frame: Day 1 (Baseline) through Day 1093

  6. Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores Over Time

    The HAQ-DI assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories is divided by the number of categories answered, yielding a score from 0-3.

    Time frame: Day 1 (Baseline) to Day 1093

07

Results

Posted Mar 26, 2012

Participant flow

Participants were enrolled at 3 locations and 32 sites worldwide: United States (20 sites), Canada (6 sites), and Mexico (6 sites).

Participant flow — Overall Study
MilestoneSubcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure)Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure)
Started5271
Completed3461
Not completed1810
Withdrew: Adverse event84
Withdrew: Withdrawal by subject31
Withdrew: Pregnancy01
Withdrew: Lost to follow-up30
Withdrew: Death11
Withdrew: Lack of efficacy33

Outcome measures

PrimaryNumber of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Treatment-related Adverse Events (AEs), AEs Leading to Discontinuation, and AEs of Interest (AEIs) at Day 85

An AE is a new or worsening illness, sign, or symptom or a clinically significant abnormal laboratory test result occurring during the study, regardless of causality, and noted by the investigators. Systemic injection reaction occurring ≤ 24 hours after dosing.

Time frame:
Day 1 (Baseline) through Day 85
Reported as:
Number · Participants
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Treatment-related Adverse Events (AEs), AEs Leading to Discontinuation, and AEs of Interest (AEIs) at Day 85
ParticipantsSubcutaneous Abatacept, 125 mg
Deaths0
SAEs1
Treatment-related SAEs0
SAEs leading to discontinuation0
Treatment-related AEs11
AEs leading to discontinuation1
AEIs: Infections20
AEIs: Malignancy0
AEIs: Automimmune disorders (prespecified)0
AEIs: Injection reactions (prespecified) Local2
AEIs: Injection reactions (prespecified) Systemic2
SecondaryMean Trough Serum Concentration (Cmin) of Abatacept

Cmin of abatacept was determined from serum samples.

Time frame:
Days 29, 85, 57, and 85
Reported as:
Geometric mean · μg/mL
Mean Trough Serum Concentration (Cmin) of Abatacept
μg/mLSubcutaneous Abatacept, 125 mg
Day 29 (n=116)34.31 ± 46
Day 57 (n=117)34.25 ± 48
Day 85 (n=118)33.78 ± 48
PrimaryNumber of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Treatment-related Adverse Events (AEs), and AEs Leading to Discontinuation

An AE is a new or worsening illness, sign, or symptom or a clinically significant abnormal laboratory test result occurring during the study, regardless of causality, and noted by the investigators.

Time frame:
Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period
Reported as:
Number · Participants
Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Treatment-related Adverse Events (AEs), and AEs Leading to Discontinuation
ParticipantsSubcutaneous Abatacept, 125 mg
Deaths4
SAEs43
Treatment-related SAEs11
SAEs leading to discontinuation8
Treatment-related AEs60
AEs leading to discontinuation11
PrimaryNumber of Participants With Hematology Laboratory Values Meeting the Criteria for Marked Abnormality

LLN=lower limit of normal; ULN=upper limit of normal; preRx=pretreatment. Marked abnormality criteria: Hemoglobin (g/dL) \>3 decrease from preRx. Hematocrit (%)\<0.75\*preRx. Erythrocytes (\*10\^6 c/uL) \<0.75\*preRx. Platelet count (\*10\^9 c/L) \<0.67\*LLN or 1.5\*ULN or, if preRx\<LLN, use \<0.5\*preRx and \<100,000 mm\^3. Leukocytes (\*10\^3 c/uL) \<0.75\*LLN or \>1.25\*ULN or, if preRx\<LLN, use \<0.8\*preRx or \>ULN or, if preRx\>ULN, use \>1.2\*preRx or \<LLN. Eosinophils \>0.750\*10\^3 c/uL. Lymphocytes \<0.750\*10\^3 c/uL or \>7.50\*10\^3 c/uL.

Time frame:
Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period
Reported as:
Number · Participants
Number of Participants With Hematology Laboratory Values Meeting the Criteria for Marked Abnormality
ParticipantsSubcutaneous Abatacept, 125 mg
Hemoglobin, low (n=120)7
Hematocrit, low (n=119)4
Erythrocytes, low (n=120)4
Platelet count, low (n=120)2
Leukocytes, low (n=120)2
Leukocytes, high (n=120)3
Eosinophils (absolute), high (n=122)12
Lymphocytes (absolute), low (n=122)15
PrimaryNumber of Participants With Liver and Kidney Function Laboratory Values Meeting the Criteria for Marked Abnormality

LLN=lower limit of normal; ULN=upper limit of normal; preRx=pretreatment. Marked abnormality criteria: Alkaline phosphatase (U/L) \>2\*ULN or if preRx\>ULN, use 3\*preRx. Alanine aminotransferase (U/L)\>3\*ULN or if preRx\>ULN, use \>4\*preRx. G-glutamyl transferase (U/L)\>2\*ULN or if preRx\>ULN, use \>3\*preRx. Blood urea nitrogen (mg/dL)\>2\*preRx. Creatinine (mg/dL)\>1.5\*preRx.

Time frame:
Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period
Reported as:
Number · Participants
Number of Participants With Liver and Kidney Function Laboratory Values Meeting the Criteria for Marked Abnormality
ParticipantsSubcutaneous Abatacept, 125 mg
Alkaline phosphatase, high (n=120)1
Aspartate aminotransferase, high (n=120)3
Alanine aminotransferase, high (n=120)6
G-glutamyl transferase, high (n=120)7
Blood urea nitrogen, high (n=120)5
Creatinine, high (n=120)11
PrimaryNumber of Participants With Electrolyte Laboratory Values Meeting the Criteria for Marked Abnormality

LLN=lower limit of normal; ULN=upper limit of normal; preRx=pretreatment. Sodium: \<0.95\*LLN or \>1.05\*ULN or if preRx\<LLN, \<0.95\*preRx or \>ULN, or if preRx\>ULN,\>1.05\*preRx or \<LLN. Potassium,serum: \<0.9\*LLN or \>1.1\*ULN or if preRx\<LLN, use \<0.9\*preRx or \>ULN or if preRx\>ULN, 1.1\*preRx or \<LLN. Phosphorus: 0.75\*LLN or 1.25\*ULN or, if preRx\<LLN, \<0.67\*preRx or \>ULN or, if preRx\>ULN, \<LLN.

Time frame:
Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period
Reported as:
Number · Participants
Number of Participants With Electrolyte Laboratory Values Meeting the Criteria for Marked Abnormality
ParticipantsSubcutaneous Abatacept, 125 mg
Sodium, serum, low (mEq/L) (n=120)2
Potassium, serum, low (mEq/L) (n=120)6
Phosphorus, inorganic, low (mg/dL) (n=120)2
PrimaryNumber of Participants With Chemistry Laboratory Values Meeting the Criteria for Marked Abnormality

LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality: .

Time frame:
Day 1 (Baseline) to up to 56 days past the last day of subcutaneous injection in the cumulative study period
Reported as:
Number · Participants
Number of Participants With Chemistry Laboratory Values Meeting the Criteria for Marked Abnormality
ParticipantsSubcutaneous Abatacept, 125 mg
Glucose, serum, low (n=122)17
Glucose, serum, high (n=122)12
Glucose, serum, fasting, low (n=59)5
Glucose, serum, fasting, high (n=59)3
Protein, total, low (n=120)1
Protein, total, high (n=120)1
Albumin, low (n=120)3
SecondaryPercentage of Participants With A Positive Anti-abatacept Response (Based on Enzyme-linked Immunosorbent Assay [ELISA]) at Day 85

Using the ELISA, any positive (titer of 400 or greater) postbaseline sample was classified as positive immunogenicity. The percentage of participants with at least 1 positive antibody response (anti-abatacept and/or anti-CTLA4-T) during the 85 days was tabulated by antibody specificity and overall.

Time frame:
Day 1 (Baseline) through Day 85
Reported as:
Number · Percentage of participants
Percentage of Participants With A Positive Anti-abatacept Response (Based on Enzyme-linked Immunosorbent Assay [ELISA]) at Day 85
Percentage of participantsSubcutaneous Abatacept, 125 mg
Anti-abatacept (n=85)8.2
Anti-CTLA4-T9 (n=122)0.8
SecondaryPercentage of Participants With A Positive Anti-abatacept Response (Based on Electrochemiluminescence [ECL] Immunoassay) at Day 85

Number of participants was tabulated using ECL assay with at least 1 positive abatacept-induced immunogenic response (CTLA4 and possibly Ig, Ig and/or Junction Region) in the first 85 days. Positive response (titers \>10) included: * A missing baseline immunogenicity measurement and a positive immunogenicity response postbaseline * A negative baseline immunogenicity response and a positive immunogenicity response postbaseline * A positive baseline immunogenicity response and a positive immunogenicity response postbaseline that has a titer value strictly greater than the baseline titer value

Time frame:
Day 1 (Baseline) through Day 85
Reported as:
Number · Percentage of participants
Percentage of Participants With A Positive Anti-abatacept Response (Based on Electrochemiluminescence [ECL] Immunoassay) at Day 85
Percentage of participantsSubcutaneous Abatacept, 125 mg
Percentage of Participants With A Positive Anti-abatacept Response (Based on Electrochemiluminescence [ECL] Immunoassay) at Day 850
SecondaryMean Disease Activity Score 28 Based on C-reactive Protein (DAS 28-CRP) Scores Over Time

The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), C-reactive protein level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)

Time frame:
Day 1 (Baseline) through Day 1093
Reported as:
Mean · Units on a scale
Mean Disease Activity Score 28 Based on C-reactive Protein (DAS 28-CRP) Scores Over Time
Units on a scaleSubcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure)Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure)
Day 29 (n=50, 69)3.60 ± 1.242.95 ± 1.31
Day 57 (n=49, 69)3.36 ± 1.112.96 ± 1.37
Day 85 (n=49, 70)3.44 ± 1.142.91 ± 1.30
Day 169 (n=48, 71)3.45 ± 1.102.93 ± 1.29
Day 253 (n=46, 71)3.60 ± 1.333.01 ± 1.21
Day 365 (n=45, 70)3.51 ± 1.323.09 ± 1.25
Day 449 (n=43, 69)3.58 ± 1.333.21 ± 1.35
Day 533 (n=43, 68)3.51 ± 1.233.08 ± 1.43
Day 617 (n=41, 67)3.31 ± 1.203.16 ± 1.37
Day 729 (n=41, 67)3.30 ± 1.123.15 ± 1.26
Day 813 (n=39, 65)3.38 ± 1.172.81 ± 1.05
Day 897 (n=38, 65)3.41 ± 1.463.02 ± 1.19
Day 981 (n=38, 65)3.32 ± 1.373.02 ± 1.28
Day 1093 (n=34, 65)3.21 ± 1.263.10 ± 1.37
SecondaryPercentage of Participants With Low Disease Activity Score (LDAS) and Disease Activity Score 28 Based on C-reactive Protein (DAS 28-CRP) Remission Over Time:

LDAS is defined as DAS 28-CRP ≤3.2. DAS 28-CRP remission is defined as DAS 28-CRP \<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), C-reactive protein level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)

Time frame:
Day 1 (Baseline) through Day 1093
Reported as:
Number · Percentage of participants
Percentage of Participants With Low Disease Activity Score (LDAS) and Disease Activity Score 28 Based on C-reactive Protein (DAS 28-CRP) Remission Over Time:
Percentage of participantsSubcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure)Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure)
LDAS Day 29 (n=50, 69)40.0 (26.4 to 53.6)68.1 (57.1 to 79.1)
Remission Day 29 (n=50, 69)24.0 (12.2 to 35.8)50.7 (38.9 to 62.5)
LDAS Day 57 (n=49, 69)44.9 (31.0 to 58.8)60.9 (49.4 to 72.4)
Remission Day 57 (n=49, 69)26.5 (14.2 to 38.9)47.8 (36.0 to 59.6)
LDAS Day 85 (n=49, 70)40.8 (27.1 to 54.6)64.3 (53.1 to 75.5)
Remission Day 85 (n=49, 70)24.5 (12.4 to 36.5)48.6 (36.9 to 60.3)
LDAS Day 169 (n=48, 71)39.6 (25.7 to 53.4)59.2 (47.7 to 70.6)
Remission Day 169 (n=48, 71)25.0 (12.8 to 37.2)49.3 (37.7 to 60.9)
LDAS Day 253 (n=46, 71)39.1 (25.0 to 53.2)66.2 (55.2 to 77.2)
Remission Day 253 (n=46, 71)30.4 (17.1 to 43.7)42.3 (30.8 to 53.7)
LDAS Day 365 (n=45, 70)40.0 (25.7 to 54.3)57.1 (45.5 to 68.7)
Remission Day 365 (n=45, 70)33.3 (19.6 to 47.1)42.9 (31.3 to 54.5)
LDAS Day 449 (n=43, 69)41.9 (27.1 to 56.6)53.6 (41.9 to 65.4)
Remission Day 449 (n=43, 69)30.2 (16.5 to 44.0)43.5 (31.8 to 55.2)
LDAS Day 533 (n=43, 68)37.2 (22.8 to 51.7)60.3 (48.7 to 71.9)
Remission Day 533 (n=43, 68)23.3 (10.6 to 35.9)48.5 (36.7 to 60.4)
LDAS Day 617 (n=41, 67)46.3 (31.1 to 61.6)53.7 (41.8 to 65.7)
Remission Day 617 (n=41, 67)29.3 (15.3 to 43.2)43.3 (31.4 to 55.1)
LDAS Day 729 (n=41, 67)41.5 (26.4 to 56.5)59.7 (48.0 to 71.4)
Remission Day 729 (n=41, 67)29.3 (15.3 to 43.2)34.3 (23.0 to 45.7)
LDAS Day 813 (n=39, 65)43.6 (28.0 to 59.2)69.2 (58.0 to 80.5)
Remission Day 813 (n=39, 65)25.6 (11.9 to 39.3)46.2 (34.0 to 58.3)
LDAS Day 897 (n=38, 65)50.0 (34.1 to 65.9)60.0 (48.1 to 71.9)
Remission Day 897 (n=38, 65)34.2 (19.1 to 49.3)43.1 (31.0 to 55.1)
DLAS Day 981 (n=38, 65)50.0 (34.1 to 65.9)64.6 (53.0 to 76.2)
Remission Day 981 (n=38, 65)42.1 (26.4 to 57.8)46.2 (34.0 to 58.3)
LDAS Day 1093 (n=34, 65)52.9 (36.2 to 69.7)58.5 (46.5 to 70.4)
Remission Day 1093 (n=34, 65)41.2 (24.6 to 57.7)50.8 (38.6 to 62.9)
SecondaryMean Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores Over Time

The HAQ-DI assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories is divided by the number of categories answered, yielding a score from 0-3.

Time frame:
Day 1 (Baseline) to Day 1093
Reported as:
Mean · Units on a scale
Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores Over Time
Units on a scaleSubcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure)Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure)
Day 29 (n=51, 69)0.98 ± 0.700.80 ± 0.67
Day 57 (n=50, 71)0.92 ± 0.680.80 ± 0.67
Day 85 (n=49, 71)0.92 ± 0.670.82 ± 0.69
Day 169 (n=49, 71)0.97 ± 0.670.87 ± 0.74
Day 253 (n=48, 71)0.97 ± 0.690.87 ± 0.73
Day 365 (n=46, 70)0.96 ± 0.660.85 ± 0.69
Day 449 (n=43, 69)0.97 ± 0.750.89 ± 0.69
Day 533 (n=43, 68)1.07 ± 0.710.94 ± 0.71
Day 617 (n=42, 67)0.99 ± 0.740.87 ± 0.69
Day 729 (n=42, 67)0.98 ± 0.740.90 ± 0.71
Day 813 (n=40, 66)1.02 ± 0.740.88 ± 0.68
Day 897 (n=39, 65)1.06 ± 0.750.89 ± 0.73
Day 981 (n=39, 65)1.02 ± 0.760.91 ± 0.69
Day 1093 (n=34, 65)0.96 ± 0.740.92 ± 0.74
PrimaryParticipants With Urinalysis Values Meeting the Criteria for Marked Abnormality

preRX=pretreatment. For all values analyzed (protein, urine; glucose, urine; blood, urine: leukocyte esterase, urine; white blood cells, urine; red blood cells, urine): If missing preRx, use \>=2 or, if value \>= 4, or if preRx=0 or 0.5, use \>=2 or, if preRx= 1, use \>=3 or, if preRx=2 or 3, use \>=4.

Time frame:
Day 1 (Baseline) through 56 days past last day of subcutaneous injection in the cumulative study period
Reported as:
Number · Participants
Participants With Urinalysis Values Meeting the Criteria for Marked Abnormality
ParticipantsSubcutaneous Abatacept, 125 mg
Protein, urine, high (n=122)12
Glucose, urine, high (n=122)8
Blood, urine, high (n=122)28
Leukocyte esterase, urine, high (n=95)32
White blood cells, urine, high (n=103)64
Red blood cells, urine, high (n=91)33
PrimaryNumber of Participants With Adverse Events of Special Interest

AEs of special interest are AEs that may be associated with the use of immunomodulatory drugs, such as infections, malignancies, autoimmune disorders, and injection reactions (defined as local injection site reactions and systemic injection reactions occurring within 24 hours of subcutaneous injection).

Time frame:
Day 1 (Baseline) to up to 56 days past the last day of subcutaneous injection in the cumulative study period
Reported as:
Number · Participants
Number of Participants With Adverse Events of Special Interest
ParticipantsSubcutaneous Abatacept, 125 mg
Infections96
Malignancies7
Prespecified autoimmune disorders7
Prespecified systemic injection reactions14
PrimaryMean Sitting Systolic and Diastolic Blood Pressure (BP)

BP was measured after the patient had been seated quietly for at least 5 minutes and recorded during the screening visit, during every office visit prior to administration of subcutaneous injections, and at study discharge or 7 days after the last dose for patients who terminated early.

Time frame:
Before injection on Days 1, 29, 57, 85, 169, 253, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, and 1821
Reported as:
Mean · mm Hg
Mean Sitting Systolic and Diastolic Blood Pressure (BP)
mm HgSubcutaneous Abatacept, 125 mg
Sitting Systolic BP Day 1121.6 ± 16.15
Sitting Systolic BP Day 29 (n=120)123.6 ± 16.08
Sitting Systolic BP Day 57 (n=120)123.9 ± 16.95
Sitting Systolic BP Day 85 (n=120)124.3 ± 16.62
Sitting Systolic BP Day 169 (n=116)124.0 ± 15.09
Sitting Systolic BP Day 253 (n=114)122.3 ± 14.58
Sitting Systolic BP Day 365 (n=114)124.1 ± 15.0
Sitting Systolic BP Day 449 (n=111)123.9 ± 15.80
Sitting Systolic BP Day 533 (n=108)123.5 ± 15.08
Sitting Systolic BP Day 617 (n=109)124.4 ± 16.03
Sitting Systolic BP Day 729 (n=108)125.2 ± 16.09
Sitting Systolic BP Day 813 (n=105)125.6 ± 16.04
Sitting Systolic BP Day 897 (n=102)122.8 ± 13.15
Sitting Systolic BP Day 981 (n=101)123.5 ± 15.44
Sitting Systolic BP Day 1093 (n=98)122.9 ± 13.46
Sitting Systolic BP Day 1177 (n=84)124.4 ± 13.66
Sitting Systolic BP Day 1261 (n=73)123.0 ± 15.29
Sitting Systolic BP Day 1345 (n=64)120.6 ± 12.27
Sitting Systolic BP Day 1457 (n=64)124.5 ± 13.17
Sitting Systolic BP Day 1541 (n=64)121.0 ± 13.75
Sitting Systolic BP Day 1625 (n=64)123.4 ± 14.71
Sitting Systolic BP Day 1709 (n=48)122.7 ± 15.55
Sitting Systolic BP Day 1821 (n=3)123.7 ± 15.18
Sitting Diastolic BP Day 1 (n=123)73.9 ± 8.83
Sitting Diastolic BP Day 29 (n=120)75.6 ± 9.28
Sitting Diastolic BP Day 57 (n=120)74.3 ± 8.82
Sitting Diastolic BP Day 85 (n=120)74.9 ± 10.37
Sitting Diastolic BP Day 169 (n=116)74.3 ± 9.19
Sitting Diastolic BP Day 253 (n=114)73.9 ± 9.96
Sitting Diastolic BP Day 365 (n=114)74.0 ± 9.98
Sitting Diastolic BP Day 449 (n=111)74.4 ± 9.53
Sitting Diastolic BP Day 533 (n=108)74.8 ± 10.08
Sitting Diastolic BP Day 617 (n=109)74.9 ± 9.72
Sitting Diastolic BP Day 79 (n=108)75.5 ± 9.83
Sitting Diastolic BP Day 813 (n=105)75.8 ± 10.20
Sitting Diastolic BP Day 897 (n=102)75.0 ± 10.23
Sitting Diastolic BP Day 981 (n=101)75.2 ± 9.35
Sitting Diastolic BP Day 1093 (n=98)76.2 ± 10.78
Sitting Diastolic BP Day1177 (n=84)77.6 ± 9.04
Sitting Diastolic BP Day 1261 (n=73)76.3 ± 9.94
Sitting Diastolic BP Day 1345 (n=64)75.4 ± 8.21
Sitting Diastolic BP Day 1457 (n=64)76.8 ± 7.14
Sitting Diastolic BP Day 1541 (n=64)75.6 ± 9.53
Sitting Diastolic BP Day 1625 (n=64)75.6 ± 9.36
Sitting Diastolic BP Day 1709 (n=48)75.2 ± 9.74
Sitting Diastolic BP Day 1821 (n=3)69.3 ± 8.14
PrimaryMean Heart Rate

Heart rate was measured after the patient had been seated quietly for at least 5 minutes and recorded during the screening visit, during every office visit prior to administration of subcutaneous injections, and at study discharge or 7 days after the last dose for patients who terminated early.

Time frame:
Before injection on Days 1, 29, 57, 85, 169, 253, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, and 1821
Reported as:
Mean · Beats per minute
Mean Heart Rate
Beats per minuteSubcutaneous Abatacept, 125 mg
Day 174.2 ± 9.56
Day 29 (n=120)74.9 ± 8.35
Day 57 (n=120)74.6 ± 8.63
Day 85 (n=120)74.5 ± 8.90
Day 169 (n=119)73.6 ± 9.05
Day 253 (n=115)73.9 ± 9.74
Day 365 (n=114)73.8 ± 9.37
Day 449 (n=111)73.5 ± 9.12
Day 533 (n=109)72.7 ± 8.41
Day 617 (n=109)73.6 ± 9.83
Day 729 (n=108)74.2 ± 9.71
Day 813 (n=105)72.8 ± 7.76
Day 897 (n=102)72.4 ± 10.05
Day 981 (n=101)73.0 ± 8.90
Day 1093 (n=98)71.9 ± 9.07
Day 1177 (n=84)72.6 ± 8.33
Day 1261 (n=73)72.3 ± 9.41
Day 1345 (n=64)72.6 ± 8.02
Day 1457 (n=64)72.1 ± 7.78
Day 1541 (n=64)72.7 ± 8.90
Day 1625 (n=64)72.5 ± 8.73
Day 1709 (n=48)74.0 ± 9.78
Day 1821 (n=3)74.0 ± 6.24
PrimaryMean Temperature

Temperature was measured after the patient had been seated quietly for at least 5 minutes and recorded during the screening visit, during every office visit prior to administration of subcutaneous injections, and at study discharge or 7 days after the last dose for patients who terminated early.

Time frame:
Before injection on Days 1, 29, 57, 85, 169, 253, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, and 1821
Reported as:
Mean · Degrees Celsius
Mean Temperature
Degrees CelsiusSubcutaneous Abatacept, 125 mg
Day 136.4 ± 0.49
Day 29 (n=120)36.4 ± 0.43
Day 57 (n=120)36.3 ± 0.40
Day 85 (n=120)36.4 ± 0.43
Day 169 (n=119)36.4 ± 0.41
Day 253 (n=115)36.4 ± 0.38
Day 365 (n=114)36.3 ± 0.39
Day 449 (n=111)36.4 ± 0.46
Day 533 (n=109)36.4 ± 0.38
Day 617 (n=109)36.4 ± 0.41
Day 729 (n=108)36.3 ± 0.33
Day 813 (n=105)36.3 ± 0.48
Day 897 (n=102)36.4 ± 0.36
Day 981 (n=101)36.4 ± 0.44
Day 1093 (n=98)36.3 ± 0.43
Day 1177 (n=84)36.3 ± 0.39
Day 1261 (n=73)36.3 ± 0.41
Day 1345 (n=64)36.3 ± 0.33
Day 1457 (n=64)36.3 ± 0.39
Day 1541 (n=64)36.2 ± 0.36
Day 1625 (n=64)36.2 ± 0.43
Day 1709 (n=48)36.2 ± 0.37
Day 1821 (n=3)36.7 ± 0.21

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Subcutaneous Abatacept, 125 mg—43/123 (35%)101/123 (82.1%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventSubcutaneous Abatacept, 125 mg
PneumoniaInfections and infestations4/123
OsteoarthritisMusculoskeletal and connective tissue disorders4/123
Hiatus herniaGastrointestinal disorders2/123
Chest painGeneral disorders2/123
Hip fractureInjury, poisoning and procedural complications2/123
CholelithiasisHepatobiliary disorders2/123
PancytopeniaBlood and lymphatic system disorders2/123
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/123
Cerebrovascular accidentNervous system disorders1/123
Colonic fistulaGastrointestinal disorders1/123
Most frequent other events
Showing 10 of 22
Most frequent other events
EventSubcutaneous Abatacept, 125 mg
NasopharyngitisInfections and infestations34/123
Upper respiratory tract infectionInfections and infestations30/123
Urinary tract infectionInfections and infestations24/123
CoughRespiratory, thoracic and mediastinal disorders17/123
BronchitisInfections and infestations14/123
Back painMusculoskeletal and connective tissue disorders13/123
HypertensionVascular disorders10/123
HeadacheNervous system disorders10/123
SinusitisInfections and infestations10/123
DizzinessNervous system disorders10/123

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure)Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure)Total
Mean56.5 ± 10.252.8 ± 13.854.3 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure)Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure)Total
Female4259101
Male101222
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Partcipants)Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure)Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure)Total
White4770117
Black/African American303
American Indian/Alaska Native101
Asian011
Other101
Region of Enrollment
Region of Enrollment(Participants)Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure)Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure)Total
North America521668
South America05555
Mean Baseline High Sensitivity C-Reactive Protein Level
Mean Baseline High Sensitivity C-Reactive Protein Level(μg/mL)Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure)Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure)Total
Mean0.94 ± 0.650.92 ± 0.880.93 ± 0.79
Mean Baseline 28 Joint Disease Activity Score (DAS 28)
Mean Baseline 28 Joint Disease Activity Score (DAS 28)(Score on a scale)Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure)Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure)Total
Mean3.55 ± 1.203.28 ± 1.293.39 ± 1.26
Mean Number of Tender Joints at Baseline
Mean Number of Tender Joints at Baseline(Joints)Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure)Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure)Total
Mean9.1 ± 12.88.8 ± 12.48.9 ± 12.5
Mean Number of Swollen Joints at Baseline
Mean Number of Swollen Joints at Baseline(Joints)Subcutaneous Abatacept, 125 mg (Prior Anti-TNF Failure)Subcutaneous Abatacept, 125 mg (Prior Methotrexate Failure)Total
Mean5.4 ± 6.44.3 ± 5.94.8 ± 6.1

1 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • Rheumatology Associates Of N. Al, P.C.
    Huntsville, Alabama 35801, United States
  • Allergy & Rheumatology Medical Clinic, Inc.
    La Jolla, California 92037, United States
  • Valerius Medical Group &Research Ctr. Of Greater Long Beach
    Long Beach, California 90806, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Inland Rheumatology Clinical Trials Inc.
    Upland, California 91786, United States
  • Arthritis & Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Diagnostic Rheumatology And Research,Pc
    Indianapolis, Indiana 46227, United States
  • Graves Gilbert Clinic
    Bowling Green, Kentucky 42101, United States
  • Physician Research Collaboration, Llc
    Lincoln, Nebraska 68516, United States
  • Innovative Health Research
    Las Vegas, Nevada 89128, United States
  • The Center For Rheumatology, Llp
    Albany, New York 12206, United States
  • The Arthritis Clinic & Carolina Bone & Joint
    Charlotte, North Carolina 28210, United States
  • Unifour Medical Research
    Hickory, North Carolina 28601, United States
  • Cincinnati Rheumatic Disease Study Group
    Cincinnati, Ohio 45219, United States
  • Portland Rheumatology Clinic
    Lake Oswego, Oregon 97035, United States
  • Rheumatic Disease Associates, Ltd.
    Willow Grove, Pennsylvania 19090, United States
  • Walter F. Chase, Md
    Austin, Texas 78705, United States
  • Arthritis Centers Of Texas
    Dallas, Texas 75246, United States
  • Local Institution
    Edmonton, Alberta T6G 2S2, Canada
  • Local Institution
    St. John'S, Newfoundland and Labrador A1A 5E8, Canada
  • Local Institution
    Kitchener, Ontario N2M 5N6, Canada
  • Local Institution
    Toronto, Ontario M5G 1X5, Canada
  • Local Institution
    Montreal, Quebec H2L 1S6, Canada
  • Local Institution
    Quebec, G1V 3M7, Canada
  • Local Institution
    Tijuana, Baja California 22320, Mexico
  • Local Institution
    Mexico, Distrito Federal 06726, Mexico
  • Local Institution
    Mexico, Distrito Federal 14080, Mexico
  • Local Institution
    Guadalajara, Jalisco 44690, Mexico
  • Local Institution
    Nuevo Leon, 64020, Mexico
  • Local Institution
    San Luis Potosi, 78240, Mexico
09

References and documents

Publications

  • Alten R, Bingham CO 3rd, Cohen SB, Curtis JR, Kelly S, Wong D, Genovese MC. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet Disord. 2016 May 26;17:231. doi: 10.1186/s12891-016-1082-z. PubMed 27229685 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Dec 2009 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2008
First posted
Apr 22, 2008
Start
May 2008
Primary completionActual
Dec 2009
CompletionActual
Jan 2012
Results first posted
Mar 26, 2012
Last update
Mar 9, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00663702
Responsible party
Sponsor
First posted
Apr 22, 2008
Start date
May 2008
Primary completion
Dec 2009
Completion
Jan 2012
Results posted
Mar 26, 2012
Last update
Mar 9, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion